Stock News

Analysts See $-0.46 EPS for OptiNose, Inc. (OPTN); Last Week Manchester United plc (MANU) Coverage

Analysts expect OptiNose, Inc. (NASDAQ:OPTN) to report $-0.46 EPS on February, 26.After having $-4.23 EPS previously, OptiNose, Inc.’s analysts see -89.13% EPS growth. The stock decreased 1.85% or $0.3 during the last trading session, reaching $15.91. About 61,949 shares traded. OptiNose, Inc. (NASDAQ:OPTN) has 0.00% since February 21, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 5 analysts covering Manchester United Ltd. (NYSE:MANU), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Manchester United Ltd. had 14 analyst reports since September 18, 2015 according to SRatingsIntel. Jefferies maintained Manchester United plc (NYSE:MANU) rating on Friday, September 22. Jefferies has “Buy” rating and $21 target. Jefferies maintained Manchester United plc (NYSE:MANU) on Monday, August 14 with “Buy” rating. Jefferies maintained it with “Buy” rating and $22.0 target in Thursday, November 16 report. The firm earned “Buy” rating on Friday, September 18 by Jefferies. Jefferies maintained Manchester United plc (NYSE:MANU) on Monday, September 18 with “Buy” rating. The stock has “Buy” rating by Jefferies on Tuesday, August 16. Gabelli initiated the shares of MANU in report on Monday, October 17 with “Buy” rating. The firm has “Outperform” rating given on Tuesday, March 15 by Credit Suisse. The rating was maintained by Jefferies on Monday, June 5 with “Buy”. See Manchester United plc (NYSE:MANU) latest ratings:

16/11/2017 Broker: Jefferies Rating: Buy New Target: $22.0 Maintain
22/09/2017 Broker: Jefferies Rating: Buy Old Target: $19 New Target: $21 Maintain
18/09/2017 Broker: Jefferies Rating: Buy New Target: $19.0 Maintain

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company has market cap of $601.68 million. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It currently has negative earnings. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.

Manchester United plc, together with its subsidiaries, owns and operates a professional sports team in the United Kingdom. The company has market cap of $3.19 billion. The firm operates Manchester United Football Club, a professional football club. It currently has negative earnings. It develops marketing and sponsorship relationships with regional and international companies to leverage its brand.

Investors sentiment decreased to 1.25 in Q3 2017. Its down 0.13, from 1.38 in 2017Q2. It dropped, as 6 investors sold Manchester United plc shares while 10 reduced holdings. 8 funds opened positions while 12 raised stakes. 33.50 million shares or 17.03% more from 28.62 million shares in 2017Q2 were reported. 15,600 were reported by Connable Office. 47,881 were accumulated by Roundview Cap Ltd. Financial Bank Of America Corp De has 0% invested in Manchester United plc (NYSE:MANU) for 34,998 shares. D E Shaw holds 0.01% or 215,254 shares in its portfolio. Lomas Management Ltd Liability stated it has 534,836 shares or 1.93% of all its holdings. Alliancebernstein L P accumulated 0% or 328,360 shares. Wells Fargo Com Mn holds 0% or 6,465 shares in its portfolio. The New York-based Bamco Ny has invested 1.23% in Manchester United plc (NYSE:MANU). Lansdowne Prtn (Uk) Llp owns 4.94 million shares or 0.93% of their US portfolio. Lindsell Train Ltd holds 4.53% or 7.47 million shares. Hanson Mcclain holds 0% in Manchester United plc (NYSE:MANU) or 5 shares. Moreover, Symmetry Peak Management Ltd has 0.04% invested in Manchester United plc (NYSE:MANU). Baldwin Brothers Ma holds 0% or 10 shares. Barclays Public Ltd Co owns 5,764 shares or 0% of their US portfolio. Morgan Stanley holds 0% of its portfolio in Manchester United plc (NYSE:MANU) for 195,952 shares.

Leave a Reply

Your email address will not be published. Required fields are marked *